Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047172 · ClinicalTrials.gov registry record · Phase 3
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
A Phase 3 study of Stroke and Intracranial Arteriosclerosis, sponsored by University of Florida.
- Active
- Registry status
- Phase 3
- Development phase
- 1,683
- Enrollment target
- 20
- Study locations
NCT05047172: Active Phase 3 study of Stroke and Intracranial Arteriosclerosis, sponsored by University of Florida.
NCT05047172 is a Phase 3 study of Stroke and Intracranial Arteriosclerosis that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 1,683 participants, below the 12,013-participant average among 454 other Stroke trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05047172, a Phase 3 study of Stroke and Intracranial Arteriosclerosis, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,683 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Primary Outcome
Non-ICH major hemorrhage is derived from the International Society on Thrombosis and Haemostasis (ISTH) criteria consisting of any of the following: * Fatal bleeding * Symptomatic bleeding in a critical area or organ, such as subarachnoid, intraventricular, subdural, epidural, spinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome * Symptomatic bleeding causing a fall in hemoglobin level of 1.24 mmol/L (20g/L or greater) or more, or lead
Conditions Studied
Interventions
- DRUG Ticagrelor + Aspirin
- DRUG Rivaroxaban + Aspirin
- DRUG Clopidogrel + Aspirin
- OTHER Risk Factor Management
Study Locations (20)
California
- Mercy San Juan Medical Center - Carmichael
- The Neuron Clinic - Chula Vista - Chula Vista
- Kaiser Permanente Fontana Medical Center - Fontana
- Long Beach Memorial Medical Center - Long Beach
- Los Alamitos Medical Center - Los Alamitos
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center, Los Angeles, CA - Los Angeles
- UC Irvine Medical Center - Orange
- UC Davis Medical Center - Sacramento
- Salinas Valley Memorial Hospital - Salinas
- UCSD Medical Center - Hillcrest Hospital - San Diego
- Providence Little Company of Mary Medical Center Torrance - Torrance
Alabama
- University of Alabama Hospital - Birmingham
- University of South Alabama University Hospital - Mobile
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic - Phoenix
Colorado
- University of Colorado Hospital - Aurora
- St. Mary's Medical Center - Grand Junction
Connecticut
- Hartford Hospital - Hartford
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,683 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 3 |
What the registry record for NCT05047172 still lists
NCT05047172 is an interventional study that assigns participants to a tested intervention. Its 1,683 participants enrollment target places it among the larger protocols in the corpus, below the 12,013-participant average among 454 other Stroke trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 4 interventions - of which Ticagrelor + Aspirin is the first listed.
NCT05047172 names 20 study sites across 5 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05047172 about?
NCT05047172 is a clinical study titled "Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis". The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
What is the current status of trial NCT05047172?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,683 participants. The study started on 2022-08-02. Estimated completion is 2028-05-31.
What conditions does trial NCT05047172 study?
This clinical trial studies the following conditions: Stroke, Intracranial Arteriosclerosis.
What interventions are being tested in trial NCT05047172?
The interventions under investigation include: Ticagrelor + Aspirin (DRUG), Rivaroxaban + Aspirin (DRUG), Clopidogrel + Aspirin (DRUG), Risk Factor Management (OTHER).
Who is sponsoring clinical trial NCT05047172?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05047172 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05047172's enrollment target sits among peer trials
1,683 29th of 454 higher than 426 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
Locomotor Experience Applied Post Stroke Trial
COMPLETED · Phase 3
-
Vitamin Therapy for Prevention of Stroke
COMPLETED · Phase 3
-
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
COMPLETED · Phase 3
-
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
COMPLETED · Phase 3
-
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI